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1. Introduction
1.1. Endocrinology of aging
Aging is inevitable. Although it has been intensively studied and discussed, its cause(s) are
still in the realm of hypotheses. Two main theories hold the center of the stage at the moment:
1) aging occurs in accordance with genetic pre- programmed events or 2) it is not genetically
programmed but results from an accumulation of random events [1, 2]. Either way, changes
in cellular/molecular function are common denominators to be found in all processes that
characterize biological aging, but these changes occur with different timing and specificity
among different cells, tissues or organs [3]. This chapter will briefly review some important
aspects of current knowledge about aging process and its impact on thyroidal function.
The endocrine system is as affected by aging as are other systems. Yet, again, not all of its
components are affected at the same time or in the same way. During aging, physiologic
functions decline gradually, cellular protein synthesis is diminished as well as immune
function. There is also an increase in fat mass, a loss of muscle mass and strength, and a decrease
in bone mineral density that contribute to declining health status.
Two important clinical changes occur in endocrine activity during aging, involving pancreas
and thyroid gland. About 40% of individuals between the ages of 65 and 74 years and 50% of
those older than 80 years have impaired glucose tolerance or diabetes mellitus, and in almost
50% of elderly adults with diabetes the disease is undiagnosed [4]. Pancreatic secretion, insulin
receptor and insulin signaling pathways changes associated with aging are critical components
of the endocrinology of aging. In addition to relatively decreased insulin secretion by the beta
cells, peripheral insulin resistance related to poor diet, physical inactivity, increased abdominal
fat mass, and decreased lean body mass contribute to the deterioration of glucose metabolism
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[4]. Other hormonal systems exhibit lowered circulating hormone concentrations during
normal aging, and these changes have been considered mainly physiologic. The decrease in
human gonadic function with consequent decline in circulating estrogen and testosterone, and
increase in serum gonadotropins (FSH and LH), is a classic example. A decrease in growth
hormone (GH) and insulin-like growth factor-I (IGF-I) are most probably due do a decline in
hypothalamic growth hormone releasing hormone (GHRH), and also a part of the aging
process in mammals [4, 5]. The aged adrenal cortex is affected in its capacity to produce
dehydroepiandrosterone (DHEA). In contrast the glucocorticoids produced in the adrenal
cortex fasciculate layer tend to be more responsive to stimuli, have a slightly delayed clearance
rate, and are less entrained to the circadian phase in aged subjects than in young ones. Although
not all authors agree [6], most report that healthy elder subjects have higher cortisol levels
presumably in response to increased corticotrophin (ACTH) secretion [7, 8]. It is difficult to
evaluate - in humans - if this discordance is gender-related. An increased hypothalamus-
pituitary-adrenal activity is also seen in aged rats, more due to an increase in hypothalamic
vasopressin (AVP) synthesis and secretion than to increases in corticotrophin releasing
hormone (CRH), and may be related to a decrease in glucocorticoid receptor activity both at
the hypothalamus/pituitary and at peripheral tissues [9, 10].
2. Problem statement
2.1. Aging and thyroid dysfunction
Age-related thyroid dysfunction is common. Lowered plasma thyroxine (T4) and increased
thyrotropin concentrations occur in 5% to 10% of elderly women [11]. Autoimmunity or an
age-associated disease frequently are the primarily cause of these abnormalities rather than a
natural consequence of the aging process. Several immunological abnormalities have been
described in aging process. A well-recognized age-associated immune abnormality is the
general production of both organ- and nonorgan-specific autoantibodies. Aging is frequently
associated with the appearance of thyroid autoantibodies, but the biological and clinical
significance of this is still unknown. Some data have shown that these thyroid autoantibodies
are rare in healthy centenarians and in other highly selected aged populations, whereas they
are frequently observed in unselected or hospitalized elderly patients, thus suggesting that
these autoantibodies are not the consequence of the aging process itself, but rather are related
to age-associated disease [12].
Thyroid autoimmunity and subclinical hypothyroidism have also been implicated in the
pathogenesis of other age-associated disorders like coronary heart disease [13]. A major,
unresolved issue is whether, and to what extent, the complex physiological changes seen in
the hypothalamus-pituitary-thyroid axis contribute to the pathogenesis of age-associated
diseases such as atherosclerosis, coronary heart disease and neurological disorders [11].
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With improvements in biochemical testing and increasing numbers of relatively asymptomatic
individuals being subjected to blood testing, subclinical hypothyroidism and subclinical
hyperthyroidism have become the most frequent thyroid disease. The clinical complications
and functional consequences and effects on quality of life have been extensively addressed as
well as the therapeutic options, however because of the lack of large randomized clinical trials,
the evidence for choosing one treatment over another is minimal [14].
Normal aging is accompanied by a slight decrease in pituitary thyrotropin (TSH) release and
especially by decreased peripheral metabolism of T4, which results in a gradual age-dependent
decline in serum triiodothyronine (T3) concentrations without changes in T4 levels [11]. This
slight decrease in plasma T3 concentrations occurs largely within the broad normal range of
the healthy elderly population and has not been clearly related to functional changes during
the aging process. The deleterious effects of overt thyroid dysfunction in elderly individuals
are clearly recognized, but the clinical relevance of mild forms of hypothyroidism and
hyperthyroidism are a matter of debate. The prevalence of thyroid disease increases with age
and all forms of thyroid disease are encountered. However, the clinical manifestations are
different from those encountered in younger patients. In the elderly, autoimmune hypothyr‐
oidism is particularly prevalent. Hyperthyroidism is mainly characterized by cardiovascular
symptoms and is frequently due to toxic nodular goiters. Thyroid carcinoma is also more
aggressive [15].
Molecular biology studies have considerably broadened our knowledge of thyroid tumori‐
genesis. Follicular cell proliferation is mainly regulated by TSH but also is controlled by extra-
cellular growth factors that essentially modify intra- cellular signaling pathways after binding
to membrane receptors. It is known that “in vitro” TSH stimulates cell cycle progression and
proliferation in cooperation with insulin or IGF-I in various thyrocyte culture systems,
including rat thyroid cell lines (FRTL-5, WRT and PCCl-3), and in primary cultures of rat, dog,
sheep and human thyroid cells [16]. Park et al. demonstrated that the TSH proliferative effect
is, at least in part, mediated by an increase in expression of an adaptor molecule of the IGF-I
receptor (p66Shc) [17]. These data suggest that the synergistic proliferative effect of TSH and
insulin/IGF-I on the thyroid gland may also occur “in vivo”.
Tumor growth occurs when the normal equilibrium of regulatory pathways is disrupted, either
through enhancement of stimulatory pathways or deficient inhibitory pathways [18]. Epide‐
miological studies show that cancer is primarily a disease of the aged. Cancer rates increase
dramatically in humans beginning in the sixth and seventh decades of life. Although the
complex relationship between cancer and aging has long been recognized, a clear understand‐
ing of the mechanisms underlying this relationship has remained elusive. Recently, Hinkal
and Donehower reviewing this issue focused on a decline in function of tumor-suppressing
genes like p53 during aging, associated with the development of tumors in many different
tissues in mice. Among the hundreds of tumor-suppressing genes now identified, p53 may be
the most important. The p53 gene is mutated in over half of all human cancers, and it has been
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estimated that more than 80% of human cancers have dysfunctional p53 signaling [19]. In fact,
decreased expression of tumor- suppressing genes, may be associated with higher cancer
incidence in aged subjects, but one can not discard higher function of genes involved in cellular
proliferation probably also present in aged subjects.
Ras proteins are involved in the transduction of growth factor signals by surface receptors,
and are key components of downstream signaling through several pathways. Ras activation
of the Raf serine/threonine kinases, and activation of the ERK mitogen-activated protein
kinases (MAPKs) is an important signaling pathway for many Ras effects [20]. Thyroidal
proliferation can be induced by growth factors, and it is known that oncogenic mutations of
Ras-family genes play an important role in malignant transformation and tumor progression
in the follicular epithelium of the thyroid gland. In fact, De Vita et al. showed in FRTL5 thyroid
cells that the overexpression of mutated RAS gene inhibits the expression of thyroid differen‐
tiation markers in a dose-dependent way [63]. Overexpression of three different Ras isoforms
(H-, K- and N-Ras) exert similar effects on the thyroid phenotype: loss of thyroid differentia‐
tion, with decrease in thyroidal differentiation markers proteins as thyroglobulin, thyroper‐
oxidase, Na+/I- symporter, TSH receptor, thyroid oxidase and thyroid specific combination of
transcription factors, Titf 1, Foxe 2 and Pax 8 [21].
Ras proteins comprise a group of 20- to 25-KDa proteins that are involved in transduction of
signals elicited by activated surface receptors, acting as molecular switches in many processes
governing cellular growth and differentiation. The Ras-pERK pathway can also be modulated
by thyroid hormones. In the hypothyroid rat there is a clear positive modulation of Ras, but
this does not affect pERK, which shows a slight decrease. In contrast, thyroidal pERK increases
in T4-induced hyperthyroidism, but there are no changes in RAS expression [22].
Effects of aging on Ras expression are still very much unexplored. In rat thyroids from both
genders aging duplicated Ras expression, but its signal transduction by pERK was decreased,
suggesting a failure in this pathway [23]. These results could be involved in the impaired
thyroidal function observed in old rats. Ras activation of Raf serine/threonine kinases, and
activation of the ERK mitogenactivated protein kinases is an important signaling pathway for
many Ras effects, the others being the activation of phosphatidylinositol-3 kinase or the Ral-
small GTPases. As far as we know, an increase in the protooncogene Ras expression in the
thyroid from aged rats has not been detected previously. Further studies are required to
elucidate the pathways involved in this increases in Ras expression during the aging process,
and to correlate them with the known morphologic and functional changes that affect the aging
thyroid gland.
2.2. Aging and hypothalamus-pituitary-thyroid axis
The effect of aging on the hypothalamus-pituitary-thyroid function is still a subject of contro‐
versies. The hypothalamus-pituitary-thyroid axis undergoes a significant number of complex
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physiological alterations associated with aging. However, direct age-related changes need to
be distinguished from indirect alterations caused by simultaneous thyroid or non- thyroidal
illness, or other physiological or pathophysiological states whose incidence increases with age.
Several changes formerly believed to be a direct result of the aging process have subsequently
been shown to be due to the increased prevalence of subclinical thyroid disease and/or the
result of non-thyroidal illness. This makes interpretation of thyroid function tests difficult in
the elderly [11].
Pituitary thyrotropin (TSH) stimulates all steps of thyroid hormones biosynthesis and is the
major regulator of the thyroid gland morphology and function. TSH production and secretion
are stimulated by the hypothalamic thyrotropin-releasing hormone (TRH) and suppressed by
thyroid hormones, in a classic negative feedback control system.
In a revision of several population studies Surks and Hollowell report that the TSH distribution
of aged humans - without thyroid disease - progressively shift to higher concentrations,
suggesting that the prevalence of subclinical hypothyroidism could have been overestimated
in many other studies [24]. The main point that is being discussed for some time by endocri‐
nologists is whether the increase in the serum immunoreactive TSH of aged subjects, and
related changes in thyroid function, are a “physiologic” consequence of aging on the hypo‐
thalamus-pituitary-thyroid axis or if they reflect alterations induced by acute or chronic non-
thyroid illnesses and/or use of drugs, both more frequent in the elder population [25, 26].
In fact there are strong evidences pointing to a decrease hypothalamus-pituitary-thyroid axis
activity with aging, be it in humans [27, 28] or in rats [29, 30, 31]. Thyroid hormone production
and metabolism are altered by aging. Serum T4 and T3 are significantly reduced in old male
rats, but the serum T3 seems to be less affected in elder female rat [30, 31, 32]. Decreases in
serum T3, associated or not with lower T4, are present in aged humans [26], however it should
be emphasized that although significantly decreased the thyroid hormone and TSH concen‐
trations mostly remain within the range considered as normal.
The decrease in T3 levels, and in the metabolism of T4 in elder subjects has been attributed to
a diminished 5’- deiodinase type I (D1) activity. In fact, we and others have found lower hepatic
and thyroid D1 activity in aging rats, but males seem to be more affected than females [30, 33,
34]. The resulting lower serum T3/T4 ratio can also be attributed, at least in part, to a prefer‐
ential release of T3 by the thyroid of the aged rat, both basal and after TSH stimulation [35].
The effect of aging on pituitary deiodinases type 1 and type 2 (D1, D2) is still awaiting further
confirmatory studies. Donda and Lemarchand-Beraud found an increase of D1 and deiodinase
type 2 (D2) activities in the pituitary of old male rats, while we found both pituitary deiodinase
activities to be decreased in the old female rat [36]. No further information seems to be
available, although suggestions of a “partial central hypothyroidism” and less efficient
response of the hypothalamic-pituitary axis to lower circulating thyroid hormones are found
often enough [32].
Hypothalamic TRH content is reduced in aged rats [32, 35] and thyrotroph response to TRH
is mostly reported as decreased, both in rats [29, 32, 36] and [37, 38] in humans. Non-stimulated
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TSH concentration has also been reported as relatively diminished by aging in a large popu‐
lation of older persons without hyperthyroidism, and in aging patients with resistance to
thyroid hormone (and their non-affected relatives) [27].
In fact, Carlé et al. detected four-fold higher average serum TSH in younger (0-20 years) than
in the older (80+ years) patients with untreated primary, spontaneous autoimmune hypothyr‐
oidism, while there was no age-dependent variation in serum T4. The well-known inverse
linear correlation between T4 and log TSH was maintained in both groups, but the serum TSH/
T4 ratio was lower in the elder patients than in the young ones. Thus, for the same degree of
thyroid failure, the serum TSH is lower among the elderly. Since serum T4 is the parameter
best associated with the degree of tissue hypothyroidism, a lower TSH at diagnosis/follow-up
of elder patients may suggest that their degree of hypothyroidism is less severe than it really
is. Furthermore, and of interest for the clinical endocrinologist, a longer time may be needed
after thyroid hormone withdrawal before elder patients with thyroid cancer reach sufficiently
high TSH values to allow an effective radioiodine treatment [28].
The increase of pituitary thyrotroph hormonal secretion, when stimulated by the low levels of
thyroid hormones, is also significantly impaired in the old rat, even when the thyroid hor‐
mones levels are dramatically reduced by MMI treatment [31]. “Normal” circulating levels of
TSH are frequently seen in aged rats, in spite of their low serum thyroid hormone levels [30,
31, 36]. This may be attributed to the secretion of a TSH with increased sialylation and
diminished biological activity [39] as reported in some types of central hypothyroidism [40]
and/or to a diminished response of the thyroid to TSH (less TSH receptors or defective
transduction of its signal). A diminished effect of a less biologically active TSH can explain the
low thyroid hormone concentration of the aged rat, that could be in part mediated by a decrease
in the TPO and Tg expression as found by us in the thyroid gland of aged male (but not female)
rat [30].
Thus, at the moment, we must consider that the hypothalamus-pituitary-thyroid axis is
affected at all three levels by normal aging, and a reduced responsiveness of target cells/tissues
to the effects of thyroid hormones levels rounds-off the picture of a mild state of “total”
hypothyroidism that occurs during the aging process, and that may vary according to gender
and species evaluated.
Aging also affect thyroid morphology, Messina et al. reported a reduction of the hypothalamus-
pituitary-thyroid axis activity, with anatomical (weight) and physiological (uptake of iodine
and hormone synthesis) age-related adaptations, that result in a reduction of thyroid function
[41]. Nevertheless, the authors consider this state as different from hypothyroidism since the
thyroid hormones tend to remain within the range considered as normal. In F344 rats, the
follicular area and the area of the follicular lumen increased and the height of follicular
epithelial cells decreased at 20.5 months, indicating low thyrocyte activity; concomitantly
serum T3, T4 and TSH concentrations also decreased with age, confirming that in F344 male
rats the aged thyroid shows structural and functional changes [42].
Figure 1 summarizes our current knowledge on aging process and its impact on thyroidal
function and regulation.
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 Figure 1. A schematic view of aging effects on thyroid regulation and function.
2.3. Subclinical hypothyroidism
The term “subclinical hypothyroidism” was first introduced in the early 1970s coincident with
the introduction of serum TSH measurements. Subclinical hypothyroidism is defined bio‐
chemically as a high serum TSH concentration and normal serum free T4 and T3 concentra‐
tions. Some investigators also consider patients who have normal basal serum TSH and
supranormal serum TSH responses to thyrotropin-releasing hormone (TRH) to have subclin‐
ical hypothyroidism. By definitions, patients with subclinical hypothyroidism cannot be
identified on the basis of symptoms and signs [43].
Subclinical hypothyroidism is present in about 4% to 8.5% of adults in the United States
who are without known thyroid disease [44]. Subtle thyroid dysfunction often affects the
oldest-old fraction of the elderly population (i.e., those >85 years). In 85-year-old healthy
individuals,  hypothyroidism  was  in  the  subsequent  4  years  associated  with  lower  all-
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cause and cardiovascular mortality rates compared with euthyroid individuals [45].  In a
group of 400 men with a mean age of 78 years, Van den Beld and colleagues [46] showed
that low serum levels of free T4 and T3 (with normal reverse T3 [rT3]) concentrations were
associated with better physical performance and 4-year survival, whereas subjects with low
serum levels of T3 and high rT3 concentrations did not show a survival advantage and had
lower levels of physical activity. These two studies support the concept that some degree
of physiologically decreased thyroid activity at the tissue level may have favorable effects
in the oldest-old subjects,  but caution should be exercised when interpreting the predic‐
tive value of thyroid dysfunction in the elderly, which may produce contradictory results
if not considered in the appropriate context [15].
Subclinical hypothyroidism has been associated with heart failure [48] and with increased odds
of metabolic syndrome [49], but the significance of increased serum TSH in elder subjects is
still sub judice. Thus, treatment of subclinical hypothyroidism to prevent heart failure and
cardiovascular disease in older people should be better evaluated in large randomized clinical
trials.
Thyroid hormones have an important role in many organic functions and their deficiency
causes a wide spectrum of clinical presentations and symptoms. Neuromuscular manifesta‐
tions are well established in overt hypothyroidism and impaired muscle function is frequently
observed. Thyroid hormone deficiency may also interfere substantially with various aspects
of physical, mental and social well-being. The evidence for improvement of psychiatric
symptoms with hormonal treatment of hypothyroidism, and the use of T3 to potentiate the
response to treatment of depressive disorders suggest a direct relationship between thyroid
hormones and psychiatric symptoms. Neurobiological evidence seems to corroborate the
hypothesis of an organic basis of the effects of thyroid hormone on the brain and on psychiatric
symptoms. There is some evidence that subclinical hypothyroidism may also be responsible
for findings classically described in hypothyroidism. Symptoms and signs of hypothyroidism
have been frequently found in subclinical hypothyroidism patients, as reported by many
authors. In fact, Reuters et al described an improvement in some physical aspects of quality of
life after L-T4 treatment in patients with subclinical hypothyroidism [50].
The frequency of subclinical hypothyroidism, varies from 6.5 to 15% in elder subjects [51, 52]
Subclinical hypothyroidism has been associated with clustering of cardiovascular risk factors,
such as hypertension, diabetes mellitus, dyslipidaemia and hyperuricaemia [53], as well as
with the development of insulin resistance, which is evident both in vivo and in vitro studies.
The latter may be attributed to decreased insulin-stimulated rates of glucose transport in cells,
due to impaired translocation of GLUT4 glucose transporters on the plasma membrane [54].
Multiple studies, with conflicting results, have examined the association of subclinical
hypothyroidism with cardiovascular risk and mortality. A recent reanalysis of the Whickham
Survey suggested a clear association of subclinical hypothyroidism with ischemic heart disease
and mortality [55]. However, a meta-analysis of 15 observational studies indicated that
increased cardiovascular risk is evident only in younger individuals with subclinical hypo‐
thyroidism [56]. In patients with type 2 diabetes mellitus, subclinical hypothyroidism has been
found to be associated with reduced all-cause mortality [57]. Furthermore, age-related subtle
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thyroid hypofunction has been related to longevity [58]. Part of the heterogeneity in these
studies may be related to differences in participants’ age, sex or TSH level. In a recent meta-
analysis combining data on 55,287 participants from 11 prospective studies, subclinical
hypothyroidism was associated with an increased risk of coronary heart disease and mortality
in patients with TSH levels higher than 10 IU/L, these associations did not differ in age, sex or
ethnicity [51].
Treatment of subclinical hypothyroidism remains controversial [52, 53, 59]. Although there
are no randomized controlled trials documenting decreased cardiovascular morbidity or
mortality, some studies have suggested that treatment of subclinical hypothyroidism may
result in improvement of cardiovascular risk factors, such as insulin sensitivity, glucose
metabolism, soluble intercellular adhesion molecule-1 [60], endothelial progenitor cell levels
[61], abnormalities in high-density lipoprotein metabolism [62], and common carotid intima-
media thickness [63]. According to the American Association of Clinical Endocrinologists,
treatment is indicated in patients with TSH levels above 10 IU/ml or in patients with TSH levels
between 5 and 10 IU/ml along with goiter or positive anti-thyroid peroxidase antibodies, since
these patients have increased rates of progression to overt hypothyroidism. However, it should
be kept in mind that TSH levels are sometimes transiently elevated, due to recovery from non-
thyroidal illness or medication use. As a result, it has been recommended that TSH measure‐
ment should be repeated after 6–8 weeks in order to confirm the diagnosis of subclinical
hypothyroidism, prior to any consideration of initiating therapy [52].
The prevalence of thyroid disease increases with age but very often presents different clinical
manifestations from those found in younger patients. Autoimmune hypothyroidism is
particularly prevalent in the elderly, and may be one of the factors that underlies an increased
serum TSH reported by various studies in this population [64]. Hyperthyroidism is less
common in among older subject, is frequently due to toxic nodular goiters, is mainly charac‐
terized by cardiovascular symptoms, and its manifestations are generally milder than in the
younger patients. The associated decrease in TSH may also be less marked than that found in
Graves’ disease. Thus, the question of whether changes in circulating TSH levels in the elderly
indicate a “physiologic adaptation” or are a reflection of associated health disturbances is still
pertinent and awaiting further evaluation.
3. Conclusion
The effect of aging on the hypothalamus-pituitary-thyroid function is still a subject of contro‐
versies. Normal aging is accompanied by a slight decrease in pituitary thyrotropin release and
especially by decreased peripheral degradation of T4, which results in a gradual age-depend‐
ent decline in serum triiodothyronine concentrations without changes in T4 levels. This slight
decrease in plasma T3 concentrations occurs largely within the broad normal range of the
healthy elderly population and has not been clearly related to functional changes during the
aging process.
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The frequency of subclinical hypothyroidism, varies from 6.5 to 15% in older subjects and
treatment of subclinical hypothyroidism remains controversial. However, it should be kept in
mind that TSH levels are sometimes transiently elevated, due to recovery from nonthyroidal
illness or medication use.
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